I am very much looking forward to some Prurisol ne
Post# of 72440
Posted On: 07/30/2013 8:53:14 AM
I am very much looking forward to some Prurisol news real soon. With Karin's comment that she was told Leo is out of country, I am sure it's for a very good business reason. I am excited about the POC trial for several reasons:
1. Excellent short term SP catalyst, as putting a drug into humans for a 2nd clinical trial for the company is great news and a significant achievement in itself
2. Rapid results - this trial is the "anti-DF" trial, in just one short month dosing will be complete and we won't have to wait long for results
3. Prurisol is the "anti-K" in the sense that we know its safe, its not completely novel, so we can hit the ground running and hopefully see some dramatic results very quickly right out of the gates
4. It will be nice to focus on Prurisol more closely as the folks at DF are obviously running a tight ship and limiting how much Leo can share, and when
5. Prurisol brings revenue discussion to the table quickly, I beleive if all goes smoothly and we get results by Oct/Nov, Leo could be at the negotiating table by xmas talking partnerships with big pharma to hit the ground running in broader phase 2/3 trials in the US in 2014
5. Prurisol is the more likely catalyst in the near term that can push SP up much higher, and make uplisting to NYSE a much more serious and timely discussion
6. NYSE uplisting opens the flood gates with institutional investors . If you think 2 million shares traded is "high" volume now, just wait until the big players start to build their position, "high" volume will take on a whole new meaning
Lots of great things in the works, as shareholders I think we will all very much enjoy having a 2nd trial in progress, as I know the pacing and info sharing out of DF has been frustrating for many, as necessary as it is to maintain trial integrity.
I hope all goes well with no snags in terms of the POC trial starting up so the above scenarios can play out quickly. But of course, delays are to be expected in biotech, so I am patient , even though I am anxious at the same time. If that makes any sense. lol
1. Excellent short term SP catalyst, as putting a drug into humans for a 2nd clinical trial for the company is great news and a significant achievement in itself
2. Rapid results - this trial is the "anti-DF" trial, in just one short month dosing will be complete and we won't have to wait long for results
3. Prurisol is the "anti-K" in the sense that we know its safe, its not completely novel, so we can hit the ground running and hopefully see some dramatic results very quickly right out of the gates
4. It will be nice to focus on Prurisol more closely as the folks at DF are obviously running a tight ship and limiting how much Leo can share, and when
5. Prurisol brings revenue discussion to the table quickly, I beleive if all goes smoothly and we get results by Oct/Nov, Leo could be at the negotiating table by xmas talking partnerships with big pharma to hit the ground running in broader phase 2/3 trials in the US in 2014
5. Prurisol is the more likely catalyst in the near term that can push SP up much higher, and make uplisting to NYSE a much more serious and timely discussion
6. NYSE uplisting opens the flood gates with institutional investors . If you think 2 million shares traded is "high" volume now, just wait until the big players start to build their position, "high" volume will take on a whole new meaning
Lots of great things in the works, as shareholders I think we will all very much enjoy having a 2nd trial in progress, as I know the pacing and info sharing out of DF has been frustrating for many, as necessary as it is to maintain trial integrity.
I hope all goes well with no snags in terms of the POC trial starting up so the above scenarios can play out quickly. But of course, delays are to be expected in biotech, so I am patient , even though I am anxious at the same time. If that makes any sense. lol
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼